Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOther Non-Current AssetsPayablesPrepaid AssetsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fennec Pharmaceuticals (FENC) Total Liabilities (2016 - 2025)

Historic Total Liabilities for Fennec Pharmaceuticals (FENC) over the last 15 years, with Q3 2025 value amounting to $53.8 million.

  • Fennec Pharmaceuticals' Total Liabilities fell 1613.15% to $53.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $53.8 million, marking a year-over-year decrease of 1613.15%. This contributed to the annual value of $50.8 million for FY2024, which is 3204.28% up from last year.
  • As of Q3 2025, Fennec Pharmaceuticals' Total Liabilities stood at $53.8 million, which was down 1613.15% from $52.3 million recorded in Q2 2025.
  • Fennec Pharmaceuticals' Total Liabilities' 5-year high stood at $66.2 million during Q1 2024, with a 5-year trough of $2.9 million in Q1 2021.
  • Over the past 5 years, Fennec Pharmaceuticals' median Total Liabilities value was $29.5 million (recorded in 2022), while the average stood at $34.3 million.
  • In the last 5 years, Fennec Pharmaceuticals' Total Liabilities surged by 34015.09% in 2023 and then tumbled by 2099.76% in 2025.
  • Quarter analysis of 5 years shows Fennec Pharmaceuticals' Total Liabilities stood at $7.0 million in 2021, then soared by 321.48% to $29.5 million in 2022, then surged by 30.43% to $38.5 million in 2023, then soared by 32.04% to $50.8 million in 2024, then rose by 5.78% to $53.8 million in 2025.
  • Its last three reported values are $53.8 million in Q3 2025, $52.3 million for Q2 2025, and $52.3 million during Q1 2025.